whitepaper
ebook: How FBDD improves hit rates & delivers high-value targets
Learn how fragment-based drug discovery improves hit rates and delivers higher-value targets using various biophysical methods.
List view / Grid view
Screening
article
The Crick HTS facility – facilitating research through large-scale screening
The high-throughput screening (HTS) facility at the Francis Crick Institute in the UK provides a core service for Crick research groups. It enables scientists to use large-scale, unbiased screening technologies and approaches as part of their research. Nikki Withers spoke to the Science Technology Platform Head, Michael Howell, to hear…
article
High-throughput screening as a method for discovering new drugs
High-throughput screening is a common method of identifying lead compounds for drug development. The most common targets are enzymes – catalytic proteins that perform chemical reactions in the cell. In this article, Matthew Lloyd discusses the opportunities and challenges associated with this approach.
article
If Columbus had a map… guiding the discovery of new drugs
Exploring large databases and selecting compounds of interest can be extremely time-consuming for researchers. Here, Sacha Javor, Horst Flotow and Jingwen Shi discuss a novel chemoinformatics approach for drug discovery.
article
Current state of NAFLD treatments and the promise of in vitro platforms towards better screening of drug candidates
The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.
whitepaper
Guide: Five ways biophysical tools help brain studies
Learn why researchers turned to biophysical methods to expose the molecular mechanisms of neurodegenerative diseases.
news
Researchers identify 27 biomarkers of COVID-19 disease severity
Mass spectrometry revealed biomarkers that could be used as drug targets for developing novel therapeutics or to predict whether a patient with COVID-19 will become severely ill.
article
Expert view: High-throughput analytics for smarter cell-line development
Combine titer and glycan screening during clone selection and cell culture optimisation to make more informed choices sooner, significantly reducing the development time for therapeutic antibodies.
whitepaper
Application note: CRISPR-Cas9 screening for target identification
The identification and validation of novel drug targets is a challenging process for drug discovery programmes.
whitepaper
Application note: High-throughput sialylation screening in combination with titer monitoring for expediting clone selection in cell-line development
Glycosylation is one of the most important post-translational modifications when developing new biologics. It has a considerable impact on product performance and variability and is therefore a critical quality attribute (CQA), influencing product safety and efficacy.
article
Expert view: CRISPR screening: a powerful approach to drug discovery and development
CRISPR screening utilises the power and precision of CRISPR-Cas9 gene editing to reveal and validate novel drug targets or to study the underlying causes of disease.
article
Expert view: Finding a translatable disease model suitable for drug discovery screening
Effective drug discovery and development greatly relies on the availability of predictive pre-clinical models.
whitepaper
Application note: Screening for optimal association and dissociation rates of ligands using a live cell binding assay
Potential drugs not only need to bind to their targets, they also need to remain bound for a specific amount of time in order to work efficiently.
news
Huntington’s update: optimal treatment times and implicated molecules
Two studies reveal the importance of timing in Huntington’s disease interventions and demonstrate interleukin-6 may play a protective role.
article
Expert view: Critical consumables: meeting the need for a steady supply of microplates
In a time when rapid screening and fast-paced drug development are necessary for fighting illness and disease, having a robust supply of high-quality, fit-for-purpose consumables is critical.
